Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of chroman derivative and its preparation method and application

A derivative, chroman technology, applied in the field of pharmacy, to achieve the effects of novel structure, improvement of intestinal microecological disorder, and excellent anti-alcoholic fatty liver disease activity in vivo

Active Publication Date: 2021-08-10
CHINA PHARM UNIV
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the research on ACC inhibitors at home and abroad is in the clinical and preclinical research stage, and no drug has been approved for marketing. It is necessary to study compounds with more diverse structural types to obtain ideal drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of chroman derivative and its preparation method and application
  • A kind of chroman derivative and its preparation method and application
  • A kind of chroman derivative and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] 8',8'-Dimethyl-1-(7-methyl-1H-indole-5-carbonyl)-7',8'-dihydro-6'H-spiro[piperidine-4,2' -pyrone[3,2-g]benzopyran]-4'(3'H)-one (I-1),

[0086]

[0087] Step 1) 1-(7-Hydroxy-2,2-dimethylchroman-6-yl) ethyl ketone

[0088] Put 8g (52.80mmol) of 2,4-dihydroxyacetophenone and 150mL of 1,4-dioxane into a 250mL three-necked flask, and stir at room temperature until completely dissolved. Add 11.20 mL (0.11 mol) boron trifluoride ether solution drop by drop, and stir at room temperature until the solution turns pink. Then, 7.19 g (0.11 mol) of isoprene in 1,4-dioxane (25 mL) was added dropwise, and the solution turned purple-black, and stirred overnight at room temperature. After the reaction was detected by TLC, saturated ammonium chloride solution (50mL) was added to the reaction solution, extracted with ethyl acetate (60mL×3), the organic phases were combined, and the organic phase was washed with saturated sodium chloride solution (50mL). It was dried over sodium sulf...

Embodiment 2

[0097] 8',8'-Dimethyl-1-(2-phenyl-1H-benzimidazole-5-carbonyl)-7',8'-dihydro-6'H-spiro[piperidine-4,2 '-Pyrone[3,2-g]benzopyran]-4'(3'H)-one (I-2)

[0098]

[0099] The synthesis procedure was the same as in Example 1, and 69 mg of white solid was obtained, with a melting point of 219-221° C. and a yield of 77%.

[0100] 1 H NMR (300MHz, DMSO-d 6 )δ13.05(s,1H),8.35–8.21(m,1H),7.87–7.69(m,3H),7.60(d,J=9.1Hz,3H),7.50(s,1H),7.25(d ,J=8.3Hz,1H),6.34(s,1H),4.21(s,2H),3.69(s,2H),2.81–2.64(m,4H),1.92(s,2H),1.84–1.71( m,4H),1.29(s,6H).MS(ESI)m / z: calculated for C 32 h 31 N 3 o 4 [M-H] - :520.2, found: 520.2.

Embodiment 3

[0102] 8',8'-Dimethyl-1-(7-methyl-2-propyl-1H-benzimidazole-5-carbonyl)-7',8'-dihydro-6'H-spiro[piper Pyridine-4,2'-pyrone[3,2-g]benzopyran]-4'(3'H)-one (I-3)

[0103]

[0104] The synthesis steps were the same as in Example 1, and 70 mg of white solid was obtained, with a melting point of 175-177° C. and a yield of 70%.

[0105] 1 H NMR (300MHz, DMSO-d 6 )δ12.19(s,1H),7.49(s,1H),7.34(s,1H),6.98(s,1H),6.33(s,1H),4.17(s,2H),2.80(t,J =7.5Hz,2H),2.72(d,J=8.9Hz,4H),2.49(s,3H),2.01–1.63(m,8H),1.29(s,6H),0.94(t,J=7.4Hz ,3H).MS(ESI)m / z: calculated for C 30 h 35 N 3 o 4 [M+Na] + :524.3,found:524.3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a chroman derivative, the structure of which is shown in formula (I): the chroman derivative provided by the invention has a novel structure, excellent ACC inhibitory activity and in vivo anti-nonalcoholic fatty liver disease activity , and can significantly reduce the transcription of fatty acid de novo synthesis genes, inflammation-related genes, and liver fibrosis-related genes; it can also improve the disturbance of intestinal microecology induced by high-fat food. The chroman derivative and its pharmaceutically acceptable salt can be used to treat or prevent non-alcoholic fatty liver disease, alcoholic fatty liver disease and metabolic syndrome, exhibit excellent drug safety, and have broad development prospects.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a chroman derivative and its preparation method and application. Background technique [0002] The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing year by year all over the world, and it has become the second most serious liver disease after viral hepatitis in China; its main feature is excessive accumulation of fat in liver cells, Including simple fatty liver (Simple fatty liver, SFL), nonalcoholic steatohepatitis (Nonalcoholic steatosis heptitis, NASH), liver fibrosis, liver cirrhosis and hepatocellular carcinoma. Nonalcoholic fatty liver disease is often accompanied by obesity, insulin resistance, hyperlipidemia and other related metabolic syndromes, and has a common part with the pathogenesis of alcoholic liver disease. At present, there is no specific treatment for nonalcoholic fatty liver disease. drug. [0003] Acetyl-CoA carboxylase (Ace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D491/20A61K31/438A61K31/4709A61K31/444A61K31/5377A61K31/506A61P1/16A61P3/00
CPCA61P1/16A61P3/00C07D491/20Y02P20/55
Inventor 张惠斌王丽蕊魏强强钱民怡高颖生周金培梅连阔胡海洋
Owner CHINA PHARM UNIV